Kosan Biosciences

Kosan Biosciences was a biopharmaceutical company specializing in the discovery and development of novel small molecule therapeutics derived from polyketides. The company utilized a proprietary technology platform to engineer polyketide synthases, enabling the creation of complex natural product-like molecules for oncology indications. Their most advanced programs included tanespimycin, a first-in-class Hsp90 inhibitor for multiple myeloma, and several epothilone analogs targeting microtubules. Kosan's innovative approach to metabolic engineering positioned it as a leader in the field of natural product drug discovery. In 2008, the company was acquired by Bristol Myers Squibb to bolster its oncology pipeline.